A practical reference on synaptogenesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
chromosome condensation The process by which eukaryotic chromosomes become shorter, thicker, denser, and more conspicuous under a microscope during prophase due to systemic coiling and supercoiling of chromatic strands of DNA in preparation for cell division.
Aromatic L-amino acid decarboxylase deficiency, also known as AADC deficiency, is a rare genetic disorder caused by mutations in the DDC gene, which encodes an enzyme called aromatic L-amino acid decarboxylase.
{\displaystyle u(r,t)={\frac {G}{4\mu }}\left(R^{2}-r^{2}\right)+[\alpha F_{2}+\beta (F_{1}-1)]{\frac {\cos \omega t}{\rho \omega }}+[\beta F_{2}-\alpha (F_{1}-1)]{\frac {\sin \omega t}{\rho \omega }}}
== Limitations and means of improvement == The main disadvantage of absorption spectrometry (AS) as well as laser absorption spectrometry (LAS) in general is that it relies on a measurement of a small change of a signal on top of a large background. Any noise introduced by the light source or the optical system will deteriorate the detectability of the technique. The sensitivity of direct absorption techniques is therefore often limited to an absorbance of ~10−3, far away from the shot noise level, which for single pass direct AS (DAS) is in the 10−7 – 10−8 range. Since this is insufficient for many types of applications, AS is seldom used in its simplest mode of operation. There are basically two ways to improve on the situation; one is to reduce the noise in the signal, the other is to increase the absorption. The former can be achieved by the use of a modulation technique, whereas the latter can be obtained by placing the gas inside a cavity in which the light passes through the sample several times, thus increasing the interaction length. If the technique is applied to trace species detection, it is also possible to enhance the signal by performing detection at wavelengths where the transitions have larger line strengths, e.g. using fundamental vibrational bands or electronic transitions.
A statistical analysis plan is a document that contains a more technical and detailed elaboration of the principal features of the analysis described in the protocol, and includes detailed procedures for executing the statistical analysis of the primary and secondary variables and other data. (ICH E9) Statistical significance
Sources: en.wikipedia.org
=== Central Europe === In 1873, Professor Friedrich J. Haberlandt first became interested in soybeans when he obtained the seeds of 19 soybean varieties at the Vienna World Exposition (Wiener Weltausstellung). He cultivated these seeds in Vienna, and soon began to distribute them throughout Central and Western Europe. In 1875, he first grew the soybeans in Vienna, then in early 1876 he sent samples of seeds to seven cooperators in central Europe, who planted and tested the seeds in the spring of 1876, with good or fairly good results in each case. Most of the farmers who received seeds from him cultivated them, then reported their results. Starting in February 1876, he published these results first in various journal articles, and finally in his magnum opus, Die Sojabohne (The Soybean) in 1878. In northern Europe, lupin (lupine) is known as the "soybean of the north".
beaker A cylindrical vessel or container with a flat bottom, most commonly a type of glassware, widely used in laboratories for a variety of purposes, such as preparing, holding, containing, collecting, or volumetrically measuring chemicals, samples, or solutions, or as a chamber in which a chemical reaction occurs. Beakers are distinguished from flasks by having straight rather than sloping sides; most beakers also have a small spout in the rim to aid pouring.
Founder, Professionals with Alzheimer's. For services to Charity. Kenneth Salter. For services to the community in Ellesmere Port, Cheshire. Cheryl Anne Sanderson. For services to Cancer Patients in Barnsley, South Yorkshire. David Saunders. For services to the community in Middlesbrough, North Yorkshire. Annie Groat Scott. For services to the community in Westray, Orkney. Pamela Mary Joyce Scull (Pamela Wingfield). Founder Principal, Wingfield School of Ballet and Dance. For services to Dance and to the community in Bristol. Sanjay Shambhu. Councillor, South Gloucestershire Council and Chair, BAME Conservatives. For Political Service. John Frederick Sharman. For services to the community in Peterborough, Cambridgeshire. Janice Sheward. Director, Cancer United. For services to People with Cancer in West Sussex. Darren Keith Sims. Founder, Daz's Rock 4 Charity. For Charitable Fundraising for Disabled and Disadvantaged Young People. Ian Robert Skinner. For services to the community in Sidmouth and the Sid Valley, Devon. Angela Ann Smith. Lately Deputy Manager, Process Controls Team, Defence Business Services. For services to Defence and to Charity. Carl Smith. Advanced Paramedic in Critical Care, East of England Ambulance Service NHS Trust, Head, Clinical Development for Emergency and Critical Care, College of Paramedics and Firefighter, Norfolk Fire and Rescue Service. For services to the NHS and to Fire and Rescue. Cheryl Barbara Smith. Leader, Girlguiding Cornwall. For services to Young People. John Alexander Alister Smyth.
Previously, there had been no detailed descriptions of their spectral properties in peer-reviewed general scientific literature. A small amount of agent A-230 was also claimed to have been synthesised in the Czech Republic in 2017 for the purpose of obtaining analytical data to help defend against these novel toxic compounds. The Soviet Union and Russia reportedly developed extremely potent fourth-generation chemical weapons from the 1970s until the early 1990s, according to a publication by two chemists, Lev Fyodorov and Vil Mirzayanov, in Moskovskiye Novosti weekly in 1992. The publication appeared just on the eve of Russia's signing of the Chemical Weapons Convention. According to Mirzayanov, the Russian Military Chemical Complex (MCC) was using defence conversion money received from the West for development of a chemical warfare facility. Mirzayanov made his disclosure out of environmental concerns. He was the head of a counter-intelligence department and performed measurements outside the chemical weapons facilities to make sure that foreign spies could not detect any traces of production. To his horror, the levels of deadly substances were eighty times greater than the maximum safe concentration. The Prosecutor-General of Russia effectively admitted the existence of Novichok agents when he brought a treason case against Mirzayanov. According to expert witness testimonies that three scientists prepared for the KGB, Novichok and other related chemical agents had indeed been produced and therefore Mirzayanov's disclosure represented high treason.
Chinese officials described these criticisms as an attempt to politicise the study. Scientists involved in the WHO report, including Liang Wannian, John Watson, and Peter Daszak, objected to the criticism, and said that the report was an example of the collaboration and dialogue required to successfully continue investigations into the matter. In a letter published in Science, a number of scientists, including Ralph Baric, argued that the accidental laboratory leak hypothesis had not been sufficiently investigated and remained possible, calling for greater clarity and additional data. Their letter was criticized by some virologists and public health experts, who said that a "hostile" and "divisive" focus on the WIV was unsupported by evidence, and would cause Chinese scientists and authorities to share less, rather than more data.
Sources: en.wikipedia.org
He received his first Golden Globe Award for Best Actor – Motion Picture Drama and nominations for an Academy Award, a BAFTA Award and a Screen Actors Guild Award. In 2006, DiCaprio starred in the crime film The Departed and the political war thriller Blood Diamond. In Scorsese's The Departed, DiCaprio played the role of Billy Costigan, a state trooper working undercover in the Irish Mob in Boston, someone he characterizes as being in a "constant 24-hour panic attack". DiCaprio especially liked the experience of working with co-star Jack Nicholson, describing a scene with him as "one of the most memorable moments" of his life as an actor. In preparation, he visited Boston to interact with people associated with the Irish Mob and gained 15 pounds (6.8 kg) of muscle. Critically acclaimed, the film grossed $291 million against a budget of $90 million, becoming DiCaprio and Scorsese's highest-grossing collaboration to that point. Peter Travers of Rolling Stone praised DiCaprio's and co-star Matt Damon's performances as "explosive, emotionally complex", but felt that Nicholson overshadowed the two. Despite DiCaprio's leading role in The Departed, the film's distributor Warner Bros. Pictures submitted his performance for a Best Supporting Actor nomination at the AMPAS to avoid internal conflict with his part in Blood Diamond. Instead, his co-star Mark Wahlberg was nominated, though DiCaprio earned other accolades for The Departed, including a Satellite Award for Best Supporting Actor and Best Actor nominations at the Golden Globes and BAFTA Awards.
== History == Beginning in 1936, Japanese ophthalmologist Tsutomu Sato conducted research in anterior and posterior keratotomy, an early form of refractive surgery that attempted to treat keratoconus, myopia and astigmatism by making incisions in the cornea. Enhanced flattening was noted with longer and deeper incisions. At first successful, Sato's technique resulted in bullous keratopathy in up to 70% of patients related to endothelial damage. In 1974, Svyatoslav Fyodorov removed glass from the eye of a boy who had been in an accident. The boy, who required eyeglasses for correction of myopia caused by astigmatism, fell off his bicycle. His glasses shattered on impact, and glass particles lodged in both eyes. To save the boy's vision, Fyodorov performed an operation which consisted of making numerous radial incisions extending from the pupil to the periphery of the cornea in a radial pattern like the spokes of a wheel. After the glass was removed by this method and the cornea healed, Fyodorov found that the boy's visual acuity had improved significantly. In 1989, about 30,000 RK surgeries were being done per year in the U.S. In 1994, this increased to approximately 250,000. In 1995, the first laser for PRK was FDA approved in the U.S., making RK obsolete.
== Pharmacokinetics == After intravenous administration in humans, methylene blue shows a multiphasic change in concentration, with a terminal half-life of 5.25 hours. The initial disappearance from blood actually reflects its movement into organs, with brain, liver, and bile all showing significantly higher concentrations than blood in rats. The overall area under the curve in oral (dry gelatin capsule) administration is only 6.5% of the AUC for IV administration; judging from rat studies, the significantly altered organ distribution plays a key role in this difference. Administration as an oral solution (500 mg in 200 mL) greatly increases the bioavailability to 72.3±23.9%. In this newer study, the terminal half-lives were reported as 18.5±11.8 hours for IV use and 18.3±7.2 hours for oral use. The tmax for oral use is 2.2 hours, compared to 0.5 hours for iv use.
=== Industrial applications === Laccases have found a wide range of application, from food additive and beverage processing to biomedical diagnosis, and as cross‐linking agents for furniture construction or in the production of biofuels. The tyrosinase‐induced polymerization of peptides offers facile access to artificial mussel foot protein analogues. Next generation universal glues can be envisioned that perform effectively even under rigorous seawater conditions and adapt to a broad range of difficult surfaces.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.